To evaluate a cost-utility of sertindole compared with commonly used antipsychotic drugs in Poland: haloperidol and risperidone in the treatment of general population of schizophrenic patients and with risperidone in a group of patients intolerant to at least one other antipsychotic agent. METHODS: Cost-utility Markov model was constructed in fi ve-year time horizon. Clinical effectiveness was assessed on the basis of RCTs, meta-analyses, observational studies and systematic reviews. The measures of effectiveness in the CUA were quality adjusted life-years (QALY) and lifeyears gained (LYG). Direct medical costs were calculated from perspective of two payers (Polish National Health Fund and patient). Cost of: oral antipsychotic treatment, inpatient care, primary health care, specialist care and adverse events treatment (extrapyramidal symptoms, sedation and weight gain) were included. Discount rates of 5% for costs and 3.5% for benefi ts were used. Utilities and disutilities associated with AEs and relapse were derived from published literature. RESULTS: In general population of schizophrenic patients cost per QALY/LYG gained, using sertindole instead of risperidone is 97,396/26,585 PLN (c22,507/6,144) respectively; cost per QALY/LYG gained, using sertindole instead of haloperidol, is 82,132/20,670 PLN (c18,980/4,777) respectively. In population intolerant to at least one other antipsychotic agent sertindole dominates risperidone (sertindole is less expensive and more effective considering both QALY/LYG gained). The sensitivity analysis indicated the robustness of the results. Obtained results are placed below the acceptability threshold (3xGDP per capita in Poland) which is about 105,500 PLN (c24,380). The 2009 weighted average exchange rate of Polish National Bank was c1 = PLN 4.3273. CONCLUSIONS: Treatment of schizophrenia with sertindole is a cost-effective strategy in comparison with risperidone and haloperidol therapy. In a group of patients intolerant to at least one other antipsychotic agent sertindole compared to risperidone is dominant strategy. A recent meta-analysis has shown that escitalopram, a selective inhibitor of serotonin reuptake, is one of the best choices when starting a treatment of moderate to severe major depressive disorder (MDD), with a favourable balance between effi cacy and tolerability. Our objective was to perform an economic evaluation of escitalopram versus citalopram in Israel. Citalopram is available as a generic drug and is included in the National Health Basket. METHODS: A decision tree model was used to assess the cost-utility of escitalopram versus citalopram in fi rst-line treatment of MDD. The model also accounted for second-, third-and fourth-line treatments for patients not responding to therapy, with an overall time horizon of 12 months. The analysis adopted a Health Maintenance Organization perspective. The main outcomes were quality-adjusted life-years (QALYs) and costs associated with local health care resource use (including drug use, and hospitalizations due to depression or suicide attempt). One-way and two-way sensitivity analyses were performed with the following parameters: probabilities of remission after initial and subsequent treatment, probabilities of relapse, suicide attempt and suicide-related death, number of hospitalization days due to a suicide attempt, costs of initial and subsequent treatments and utility values. In addition, we used a Monte Carlo simulation. RESULTS: Compared to citalopram, escitalopram was more effective in terms of QALYs at a small incremental cost. The average QALYs of patients treated with escitalopram and citalopram were 0.728 and 0.720 respectively. The average cost of patients treated with escitalopram and citalopram were c105 and c63 respectively. The incremental cost-utility ratio was c5,150 (NIS23,875) per QALY. The variation of remission rates had the most infl uence on this ratio in the sensitivity analyses. CONCLUSIONS: This local economic evaluation shows that compared to citalopram, escitalopram should be the preferred option in depression in Israel with an acceptable cost per QALY.
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PMH42 UTILIZATION OF ANTIDEPRESSANTS IN SLOVAKIA
Bellová K 1 , Gatialová K 1 , Foltanova T 2 , Petrová L 1 , Bielik J 3 1 Comenius University, Bratislava, Slovak Republic; 2 Faculty of Pharmacy, Bratislava, Slovak Republic; 3 AD University, Tren ín, Slovak Republic OBJECTIVES: The main objective was to evaluate the consumption of antidepressants, it s utilization as the basic aspect of the quality of life and to analyze the using of the original drugs or generics and to show the pharmacoeconomical impact of this group of drugs considering to it s fi nancial costingness. METHODS: We used the analysis of consumption trend of antidepressants and the analysis of the trend of prices of antidepressants. We compared the original and generic market with antidepressants in Slovakia, we monitored and compared the prices for DDD and we evaluate the impact of new generics on the prices of originals as well. RESULTS: The consumption of antidepressants has increased because of increasing number depression illnesses which could be continually treated by modern antidepressants since successful treatment depends on relaps prevention. Such outcome could be reached by usage of the latest antidepressants with good compliance (escitalopram, venlafaxine, mirtazapin) . Since 2005 the consumption (packages sold) of antidepressant increased by 29% whereas the sales value stagnated as result of declining price. The price for daily recommended dosage decreased by 52.7% (from c0.80 in 2001 to c0.38 in 2008). This was infl uenced mainly by the increasing number of generics medicaments which pushed the price down. In 2009 the price of original antidepressants fall by 26.4% as reason of generic molecules. Based on long-term surveys the similar trend could be expected also in the future. CONCLUSIONS: The utilization of antidepressants lead to better quality of life. From the pharmacoeconomical view, the development of new molecules goes hand in hand with the decrease of invalidation, decrease of the cost for hospitalization, as well as increase people 's ability to take care about themselves. On the other hand, the generic substitution leads to increase of the amount of treated patients. All-cause health care utilization in the 12-months before and after treatment initiation was compared for patients and for the subset of patients with pre-period unexplained pain (UPain). Generalized Estimating Equation models were used to identify factors associated with the pre-post differences in hospitalization rates. Covariates included age, gender, pre-period comorbid conditions and medication use. RESULTS: A total of 909 patients were identifi ed (mean age = 49.6; female = 67.7%), and 45% experienced UPain. Three-quarters of patients were prescribed a SSRI and 11% were untreated with antidepressants before initiating duloxetine. Among patients, the rate of hospitalization was higher in the pre-period compared to the post-period (20.7% vs.16.5%, p = 0.006). There were no signifi cant pre-post differences in the rates of accident & emergency visits, specialist referrals, or analgesic use. Among patients with UPain, fewer were hospitalized (26.2% vs. 19.1%, p = 0.003) or received analgesic in the post-period (77.0% vs. 71.7%, p = 0.015). Multivariate analysis confi rmed fewer patients experienced hospitalization after duloxetine initiation. All depressed patients with pre-period anxiolytic use (OR = 0.70, 95% CI, 0.50-0.97, p = 0.033) or UPain patients with pre-period anticonvulsant use (OR = 0.44, 95% CI, 0.21-0.91, p = 0.026) experienced a decreased hospitalization rate after initiating duloxetine and the magnitude of change was larger than that for patients not receiving these medications. All depressed patients with pre-period alcohol/drug dependence (OR = 1.83, 95% CI, 1.01-3.30, p = 0.045) and sleep disorder (OR = 1.65, 95% CI, 1.05-2.59, p = 0.031) had an increase in the hospitalization rate from the pre-to post-period, while those without the conditions had a decreased hospitalization rate. CONCLUSIONS: Hospitalization rates were lower following duloxetine initiation among depressed patients. Pre-period alcohol/drug dependence, sleep disorders, anxiolytic and anticonvulsant use were associated with the pre-post difference in the hospitalization rate.
PMH43 HEALTH CARE UTILIZATION OF PATIENTS WITH DEPRESSION BEFORE AND AFTER INTIATING DULOXETINE

PMH44 AN OBSERVATIONAL STUDY OF THE BURDEN OF INFORMAL CAREGIVERS TO OUT-PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS
Flyckt L 1 , Granström O 2 , Löthman A 3 , Jörgensen L 2 , Koernig T 2 1 Norra Stockholms Psykiatri, Danderyd, Sweden; 2 AstraZeneca Nordic MC, Södertälje, Sweden; 3 Psykiatricentrum Väst, Bromma, Sweden OBJECTIVES: The lifetime emotional, social, and fi nancial consequences experienced by individuals with schizophrenia spectrum disorders have signifi cant effects on their families. Therefore, it is essential to increase the knowledge and awareness of the informal caregiver burden. Here, the purpose was to study objective burden (time and money spent), as well as subjective burden (care-related quality of life) of informal caregivers to patients with schizophrenia spectrum disorders. METHODS: Patients with schizophrenia spectrum disorders and their closest informal caregivers were recruited and patient-and caregiver-related characteristics and variables related to the provision of formal care were assessed. The subjective burden was assessed using the CarerQol. The objective burden was assessed prospectively during four weeks with daily recordings by the caregiver using diaries of the money and time spent on the patient. Data was analyzed using descriptive statistics. RESULTS: One-hundred and seven patients (53% females; mean age 43 ± 11 years) from nine centers in Sweden, and 118 of their closest informal care-givers (67% females; mean age 58 ± 15 years) entered the study. The mean (standard deviation, SD) GAF for the patients was 52 (11). Subjective burden (CarerQol VAS) correlated positively to GAF. The mean (SD) time spent on caring for relatives with schizophrenia spectrum disorders was 22 (36) hours per week. Half of this (11 hours) was "stand-by" time and another 5 hours were spent on household work. Caregivers' mean (SD) monthly expenses in support
